Molina Healthcare earnings release, July 22, 2026
News Release
Investor Contact:
Jeffrey Geyer,
Jeffrey.Geyer@molinahealthcare.com, 305-317-3012
Media Contact:
Caroline Zubieta,
Caroline.Zubieta@molinahealthcare.com, 562-542-1845
Molina Healthcare Reports Second Quarter 2026 Financial Results
Increases Full Year 2026 Earnings Guidance
Long Beach, Calif., July 22, 2026 – Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported second quarter 2026 GAAP income per diluted share of $1.19 and adjusted income per diluted share of $1.51. Financial results are summarized below:
Quarter Highlights
• As of June 30, 2026, the Company served approximately 4.9 million members.
• Premium revenue was approximately $10.2 billion for the second quarter of 2026.
• Second quarter 2026 GAAP income per diluted share was $1.19 and adjusted income per diluted share was $1.51.
• The Company increased its full year 2026 adjusted earnings guidance by $0.25 to at least $5.25 per diluted share.
“Our second quarter results and full year guidance reflect solid performance in our Medicaid and Medicare segments,” said Joseph Zubretsky, President and Chief Executive Officer. “The imbalance between Medicaid rates and medical cost trend appears to have stabilized and is well positioned to be corrected with future rate increases. This reinforces our belief that 2026 is the trough year for Medicaid pretax margins. We remain confident in our disciplined approach to medical cost management and believe the premium and EPS building blocks position us well for profitable growth in 2027.”
-MORE-
Molina Healthcare, Inc. Reports Second Quarter 2026 Financial Results
Page 2
July 22, 2026
Premium Revenue
Premium revenue was approximately $10.2 billion for the second quarter of 2026, a decrease of 6% year over year. The lower premium revenue reflects the impact of lower membership, partially offset by rate updates.
Net Income
GAAP net income for the second quarter of 2026 was $60 million, or $1.19 per diluted share, a decrease of 76% year over year. Adjusted net income for the second quarter of 2026 was $77 million, or $1.51 per diluted share, a decrease of 74% year over year. The decrease is attributed mainly to the lower premium revenues and increase in MCR.
Medical Care Ratio (MCR)
• The consolidated MCR for the second quarter of 2026 was 92.2%.
• The Medicaid MCR for the second quarter of 2026 was 92.7% and in line with the Company’s expectation, reflecting rate updates and stable medical cost trend.
• The Medicare MCR for the second quarter of 2026 was 90.7% and better than the Company’s expectation, reflecting lower medical cost trend and pricing implemented for 2026.
• The Marketplace MCR for the second quarter of 2026 was 88.9% and higher than the Company’s expectations, reflecting prior year risk adjustment and program integrity initiatives and the impact of current year unfavorable member acuity mix.
General and Administrative Expense Ratio
The G&A ratio and the adjusted G&A ratio for the second quarter of 2026 were 6.7% and 6.5%, respectively, reflecting continued operating discipline.
Balance Sheet
Cash and investments at the parent company were approximately $290 million as of June 30, 2026, compared to $223 million as of December 31, 2025.
Days in claims payable at June 30, 2026, was 44.
Cash Flow
Operating cash flow for the six months ended June 30, 2026, was $788 million, compared to an outflow of $112 million for the six months ended June 30, 2025. The increase compared to the prior year was driven mainly by the timing of government receivables and payables.
2026 Guidance
Premium revenue guidance for the full year is unchanged at approximately $42 billion.
The Company increased its full year 2026 GAAP earnings to at least $2.15 per diluted share and its full year 2026 adjusted earnings to at least $5.25 per diluted share. The increase to earnings guidance reflects first half performance in Medicaid. Based on developing medical cost trends, a $1.50 increase in earnings per share in Medicare is offset by a $1.50 decrease related to Marketplace. Excluding the downward revision in the Marketplace guidance, the full year guidance would have increased to $6.75 per share.
Full year guidance includes a loss of $1.50 per share due to the implementation of the new Florida Medicaid contract in the fourth quarter of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD product, which the Company previously announced it will exit for 2027.
-MORE-
Molina Healthcare, Inc. Reports Second Quarter 2026 Financial Results
Page 3
July 22, 2026
Conference Call
Management will host a conference call and webcast to discuss Molina Healthcare’s second quarter ended June 30, 2026 results, at 8:00 a.m. Eastern Time on Thursday, July 23, 2026. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 8631129. A telephonic replay of the conference call will be available through Thursday, July 30, 2026, by dialing (855) 669-9658 and entering confirmation number 6469068.
A live audio broadcast of this conference call will be available on Molina Healthcare’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com.
Financial statements
Income Statement
Three months ended (in millions)
| Three months ended – June 30, – 2026 | Three months ended – June 30, – 2025 | Six months ended – June 30, – 2026 | Six months ended – June 30, – 2025 | ||
|---|---|---|---|---|---|
| Premium Revenue | 10,244 | 10,868 | 20,416 | 21,496 | |
| Total Revenue | 10,874 | 11,427 | 21,670 | 22,574 | |
| GAAP: | Net Income | 60 | 255 | 74 | 553 |
| GAAP: | EPS – Diluted | 1.19 | 4.75 | 1.46 | 10.19 |
| GAAP: | Medical Care Ratio (MCR) | 92.2 | 90.4 | 91.6 | 89.8 |
| GAAP: | G&A Ratio | 6.7 | 6.2 | 6.9 | 6.6 |
| GAAP: | Pre-tax Margin | 0.8 | 2.8 | 0.6 | 3.2 |
| Adjusted: | Net Income | 77 | 294 | 197 | 627 |
| Adjusted: | EPS – Diluted | 1.51 | 5.48 | 3.86 | 11.56 |
| Adjusted: | G&A Ratio | 6.5 | 6.1 | 6.7 | 6.4 |
| Adjusted: | Pre-tax Margin | 1 | 3.3 | 1.3 | 3.6 |
Income Statement
Three Months Ended — UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (in millions)
| Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 | ||
|---|---|---|---|---|---|
| Revenue: | Premium revenue | 10,244 | 10,868 | 20,416 | 21,496 |
| Revenue: | Premium tax revenue | 505 | 431 | 1,009 | 819 |
| Revenue: | Investment income | 101 | 106 | 199 | 214 |
| Revenue: | Other revenue | 24 | 22 | 46 | 45 |
| Revenue: | Total revenue | 10,874 | 11,427 | 21,670 | 22,574 |
| Operating expenses: | Medical care costs | 9,440 | 9,829 | 18,710 | 19,308 |
| Operating expenses: | General and administrative expenses | 724 | 711 | 1,503 | 1,485 |
| Operating expenses: | Premium tax expenses | 505 | 431 | 1,009 | 819 |
| Operating expenses: | Depreciation and amortization | 40 | 58 | 79 | 106 |
| Operating expenses: | Impairment | 93 | |||
| Operating expenses: | Other | 20 | 25 | 48 | 50 |
| Operating expenses: | Total operating expenses | 10,729 | 11,054 | 21,442 | 21,768 |
| Operating expenses: | Operating income | 145 | 373 | 228 | 806 |
| Operating expenses: | Interest expense | 54 | 48 | 108 | 91 |
| Operating expenses: | Income before income tax expense | 91 | 325 | 120 | 715 |
| Operating expenses: | Income tax expense | 31 | 70 | 46 | 162 |
| Operating expenses: | Net income | 60 | 255 | 74 | 553 |
| Operating expenses: | Net income per share – Diluted | 1.19 | 4.75 | 1.46 | 10.19 |
| Operating expenses: | Diluted weighted average shares outstanding | 51.3 | 53.7 | 51.2 | 54.3 |
Balance Sheet
December 31, — CONSOLIDATED BALANCE SHEETS (in millions)
| June 30, – 2026 – Unaudited – ASSETS | December 31, – 2025 – ASSETS | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 4,985 | 4,248 |
| Current assets: | Investments | 3,930 | 4,008 |
| Current assets: | Receivables | 3,485 | 3,533 |
| Current assets: | Prepaid expenses and other current assets | 528 | 655 |
| Current assets: | Total current assets | 12,928 | 12,444 |
| Current assets: | Property, equipment, and capitalized software, net | 311 | 301 |
| Current assets: | Goodwill and intangible assets, net | 2,082 | 2,195 |
| Current assets: | Restricted investments | 313 | 299 |
| Current assets: | Deferred income taxes, net | 229 | 178 |
| Current assets: | Other assets | 140 | 147 |
| Current assets: | Total assets | 16,003 | 15,564 |
| Current liabilities: | Medical claims and benefits payable | 4,841 | 4,887 |
| Current liabilities: | Amounts due government agencies | 1,651 | 1,326 |
| Current liabilities: | Accounts payable, accrued liabilities and other | 1,139 | 1,093 |
| Current liabilities: | Deferred revenue | 69 | 66 |
| Current liabilities: | Total current liabilities | 7,700 | 7,372 |
| Current liabilities: | Long-term debt | 3,769 | 3,766 |
| Current liabilities: | Finance lease liabilities | 184 | 184 |
| Current liabilities: | Other long-term liabilities | 179 | 173 |
| Current liabilities: | Total liabilities | 11,832 | 11,495 |
| Stockholders’ equity: | Additional paid-in capital | 511 | 452 |
| Stockholders’ equity: | Accumulated other comprehensive (loss) income | -16 | 15 |
| Stockholders’ equity: | Retained earnings | 3,676 | 3,602 |
| Stockholders’ equity: | Total stockholders’ equity | 4,171 | 4,069 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 16,003 | 15,564 |
Cash Flow
Six Months Ended — UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions)
| Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 | ||
|---|---|---|---|
| Operating activities: | Net income | 74 | 553 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Depreciation and amortization | 79 | 106 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Deferred income taxes | -41 | 22 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Share-based compensation | 59 | 30 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Impairment | 93 | |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Other, net | -2 | |
| Changes in operating assets and liabilities: | Receivables | 48 | -466 |
| Changes in operating assets and liabilities: | Prepaid expenses and other current assets | 9 | 10 |
| Changes in operating assets and liabilities: | Medical claims and benefits payable | -46 | -50 |
| Changes in operating assets and liabilities: | Amounts due government agencies | 325 | -81 |
| Changes in operating assets and liabilities: | Accounts payable, accrued liabilities and other | 66 | -301 |
| Changes in operating assets and liabilities: | Deferred revenue | 3 | -59 |
| Changes in operating assets and liabilities: | Income taxes | 121 | 124 |
| Changes in operating assets and liabilities: | Net cash provided by (used in) operating activities | 788 | -112 |
| Investing activities: | Purchases of investments | -626 | -421 |
| Investing activities: | Proceeds from sales and maturities of investments | 672 | 717 |
| Investing activities: | Purchases of property, equipment, and capitalized software | -57 | -64 |
| Investing activities: | Net cash paid in business combinations | -245 | |
| Investing activities: | Other, net | -8 | 18 |
Full release
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995... (truncated)ange Act of 1934. Forward-looking statements provide current expectations of future events based on certain assumptions, and all statements other than statements of historical fact contained in this earnings release and the Company’s accompanying oral remarks may be forward-looking statements. In some cases, you can identify forward-looking statements by words such as “guidance,” “future,” “anticipates,” “assumes,” “believes,” “embedded,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding the Company’s 2026 guidance and long-term performance outlook, trends with respect to rates, pretax margins, utilization, and medical costs, including the timing thereof and the anticipated impact on the Company’s business, and our management’s plans and objectives for future operations and business strategy.
Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025, which is on file with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Report on Form 10-Q for the period ended March 31, 2026 filed with the SEC and Quarterly Report on Form 10-Q for the period ended June 30, 2026, to be filed with the SEC.
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of July 22, 2026, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations.
-MORE-
Molina Healthcare, Inc. Reports Second Quarter 2026 Financial Results
Page 4
July 22, 2026